SCHEMBL1808446

SCHEMBL1808446

NC1Nc2c(ccc3ccccc23)S1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.38
HSD17B10 Q99714 3/20 0.38
TSHR P16473 3/20 0.38
CYP2A6 P11509 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
HPRT1 P00492 2/20 0.35
KDM1A O60341 1/20 0.33
HIF1A Q16665 1/20 0.33
CYP1B1 Q16678 1/20 0.33
HPGD P15428 2/20 0.32
CYP3A4 P08684 1/20 0.32
KEAP1 Q14145 1/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA4 P22748 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
ANPEP P15144 1/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11316344 0.79 TAAR1 (0.38) ALDH1A1HSD17B10TSHRCYP2A6TDP1
SCHEMBL7707517 0.68 RELA (0.38) ALDH1A1CYP1B1HPGDLMNAKDM4E
SCHEMBL2176719 0.67 MEN1 (0.36) ALDH1A1CYP2A6CYP1A2MEN1KMT2A
SCHEMBL3360910 0.63 ALDH1A1 (0.41) ALDH1A1HSD17B10TSHRCYP2A6TDP1
SCHEMBL1790645 0.63 ALDH1A1 (0.41) ALDH1A1HSD17B10TSHRCYP2A6TDP1
Phenanthrene SCHEMBL28656793 0.63 CYP2A6 (0.92) ALDH1A1HSD17B10TSHRCYP2A6TDP1
SCHEMBL10448671 0.62 ALDH1A1 (0.39) ALDH1A1HSD17B10TSHRCYP2A6TDP1
SCHEMBL26797 0.61 NOX1 (0.55) ALDH1A1HSD17B10TSHRCYP2A6TDP1
SCHEMBL18059289 0.61 ANPEP (0.41) ALDH1A1HSD17B10TSHRCYP2A6TDP1
Phenanthrene SCHEMBL7643 0.60 CYP2A6 (1.00) ALDH1A1HSD17B10TSHRCYP2A6TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951814-B2 Quinazolinedione derivatives as TRPA1 modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2011-05-31 US disclosed
WO-2010004390-A1 QUINAZOLINE DIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-01-14 WO disclosed
US-20090325987-A1 QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2009-12-31 US disclosed
WO-2009118596-A2 PHTHALIMIDE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S. A. (CH) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325987-A1 QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS TRPA1, TRPV1, TRPC3 ALDH1A1 871/4885HSD17B10 2398/4885TSHR 1529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.